ReNeuron touts promising results from stem cell trial

05/17/2013 | Bloomberg

Researchers are set to announce positive results from a trial of ReNeuron Group's stem cell treatment for the damage caused by stroke, CEO Michael Hunt said. The findings are expected to be presented this month at a conference in London. "It sets us up nicely for a Phase II efficacy trial," said Hunt.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD